Rigel Pharmaceuticals publishes corporate presentation outlining commercial growth strategy and pipeline priorities

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

RIGL

0.00
  • Rigel outlined a growth strategy centered on expanding its commercial portfolio, maintaining financial discipline, advancing its pipeline, and pursuing in-licensing.
  • In-licensed VEPPANU (vepdegestrant), an FDA-approved oral PROTAC for 2L+ ESR1-mutated ER+/HER2- metastatic breast cancer.
  • License economics include USD 70 million upfront, USD 15 million transition payments, up to USD 320 million in regulatory and commercial milestones.
  • Net product sales guidance set at USD 260 million; annual net product sales rose to USD 232 million in 2025 from USD 144.9 million in 2024.
  • Q1 2026 net product sales were USD 54.9 million, up 26% year over year; collaboration revenue included USD 1.8 million each from Grifols and Kissei.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.